MPO-ANCA-Positive Anti-glomerular Basement Membrane Antibody Disease Successfully Treated by Plasma Exchange and Immunosuppressive Therapy

REFERENCES

• Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma-exchange in the treatment of Goodpasture’s syndrome. Lancet. 1976;1:711–715.
   PubMed Web of Science ®Google Scholar
• Bolton WK. Goodpasture’s syndrome. Kidney Int. 1996;50:1753–1766.
   PubMed Web of Science ®Google Scholar
• Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033–1042.
   PubMed Web of Science ®Google Scholar
• Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535–1540.
   PubMed Web of Science ®Google Scholar
• Hirayama K, Yamagata K, Kobayashi M, Koyama A. Anti-glomerular basement membrane antibody disease in Japan: Part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol. 2008;12:339–347.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37:965–970.
   PubMed Web of Science ®Google Scholar
• Rutgers A, Meyers KE, Canziani G, Kalluri R, Lin J, Madaio MP. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. Kidney Int. 2000;58:115–122.
   PubMedGoogle Scholar
• Yang R, Hellmark T, Zhao J, . Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with Goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2007;18:1338–1343.
   PubMed Web of Science ®Google Scholar
• Bosch X, Mirapeix E, Font J, . Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol. 1991;36:107–113.
   PubMed Web of Science ®Google Scholar
• Segelmark M, Hellmark T, Wieslander J. The prognostic significance in Goodpasture’s disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract. 2003;94:c59–c68.
   PubMedGoogle Scholar
• Cui Z, Zhao MH, Xin G, Wang HY. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract. 2005;99:c49–c55.
   PubMedGoogle Scholar
• Merkel F, Pullig O, Marx M, Netzer KO, Weber M. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: Report of 35 cases. Nephrol Dial Transplant. 1994;9:372–376.
   PubMed Web of Science ®Google Scholar
• Daly C, Conlon PJ, Medwar W, Walshe JJ. Characteristics and outcome of anti-glomerular basement membrane disease: A single-center experience. Ren Fail. 1996;18:105–112.
   PubMed Web of Science ®Google Scholar
• Walker RG, Scheinkestel C, Becker GJ, Owen JE, Dowling JP, Kincaid-Smith P. Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture’s syndrome. Q J Med. 1985;54:75–89.
   PubMedGoogle Scholar
• Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967;126:989–1004.
   PubMed Web of Science ®Google Scholar
• Johnson JP, Moore J, Jr, Austin HA, III, Balow JE, Antonovych TT, Wilson CB. Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore). 1985;64:219–227.
   PubMed Web of Science ®Google Scholar
• Couser WG. Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988;11:449–464.
   PubMed Web of Science ®Google Scholar
• Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003;64:1535–1550.
   PubMed Web of Science ®Google Scholar
• Salama AD, Chaudhry AN, Holthaus KA, . Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture’s (anti-GBM) disease. Kidney Int. 2003;64:1685–1694.
   PubMedGoogle Scholar
• Wolf D, Hochegger K, Wolf AM, CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol. 2005;16:1360–1370.
   PubMed Web of Science ®Google Scholar
• Hellmark T, Segelmark M, Unger C, Burkhardt H, Saus J, Wieslander J. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int. 1999;55:936–944.
   PubMed Web of Science ®Google Scholar
• Yang R, Hellmark T, Zhao J, . Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. Nephrol Dial Transplant. 2009;24:1838–1844.
   PubMed Web of Science ®Google Scholar